This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Thomas Andrew Crockett net worth and biography

Thomas Crockett Biography and Net Worth

CEO of KalVista Pharmaceuticals

Andrew is a co-founder of KalVista Pharmaceuticals and its CEO. Prior to KalVista, Andrew held various senior management positions including Chief Executive, Vice President of Business Development, and Director of Clinical and Regulatory Affairs in biotech and specialty pharmaceutical companies in the United States and the United Kingdom. During his career, he has identified, negotiated, and executed strategic corporate transactions on a global basis, including mergers and acquisitions, national and international product licenses, IP and technology licenses, and R&D alliances.

Andrew received a BA from the University of Utah, and an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.

What is Thomas Andrew Crockett's net worth?: The estimated net worth of Thomas Andrew Crockett is at least $2.19 million as of February 20th, 2024. Mr. Crockett owns 211,203 shares of KalVista Pharmaceuticals stock worth more than $2,185,951 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Crockett may own. Learn More about Thomas Andrew Crockett's net worth.
How do I contact Thomas Andrew Crockett?: The corporate mailing address for Mr. Crockett and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Thomas Andrew Crockett's contact information.
Has Thomas Andrew Crockett been buying or selling shares of KalVista Pharmaceuticals?: Thomas Andrew Crockett has not been actively trading shares of KalVista Pharmaceuticals during the past quarter. Most recently, Thomas Andrew Crockett sold 24,888 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a transaction totalling $351,169.68. Following the completion of the sale, the chief executive officer now directly owns 211,203 shares of the company's stock, valued at $2,980,074.33. Learn More on Thomas Andrew Crockett's trading history.
Who are KalVista Pharmaceuticals' active insiders?: KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.
Are insiders buying or selling shares of KalVista Pharmaceuticals?: During the last year, KalVista Pharmaceuticals insiders bought shares 13 times. They purchased a total of 448,522 shares worth more than $5,806,280.30. During the last year, insiders at the specialty pharmaceutical company sold shares 13 times. They sold a total of 212,109 shares worth more than $2,650,351.15. The most recent insider tranaction occured on February, 20th when insider Edward P Feener sold 28,288 shares worth more than $398,012.16. Insiders at KalVista Pharmaceuticals own 12.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.
Information on this page was last updated on 2/20/2024.

Thomas Andrew Crockett Insider Trading History at KalVista Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2024	Sell	24,888	$14.11	$351,169.68	211,203
12/27/2023	Sell	30,000	$12.02	$360,600.00	127,532
8/18/2023	Sell	14,876	$10.73	$159,619.48	146,756
5/18/2023	Sell	5,627	$10.14	$57,057.78	128,050
2/17/2023	Sell	6,700	$7.66	$51,322.00	120,927
11/18/2022	Sell	1,785	$5.44	$9,710.40	114,878
8/17/2022	Sell	1,797	$14.96	$26,883.12	112,178
3/9/2022	Sell	10,000	$17.07	$170,700.00
10/1/2021	Sell	10,000	$17.18	$171,800.00
7/1/2021	Sell	10,000	$24.15	$241,500.00
6/17/2021	Sell	1,067	$30.04	$32,052.68	144,670
6/9/2021	Sell	8,933	$30.05	$268,436.65
4/1/2021	Sell	10,000	$27.44	$274,400.00	168,720
2/23/2021	Sell	10,000	$33.55	$335,500.00
10/20/2020	Sell	15,994	$17.49	$279,735.06	222,741
10/16/2020	Sell	1,261	$17.01	$21,449.61	236,959
12/16/2019	Sell	5,400	$17.06	$92,124.00	248,320
12/12/2019	Sell	100	$17.00	$1,700.00	248,320
7/15/2019	Sell	10,000	$17.04	$170,400.00	248,510
4/15/2019	Sell	10,000	$24.80	$248,000.00	258,810
3/14/2019	Sell	3,000	$30.16	$90,480.00	268,510
1/14/2019	Sell	10,000	$19.33	$193,300.00	272,411

Thomas Andrew Crockett Buying and Selling Activity at KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $10.35

$10.32

$11.18

50 Day Range

MA: $12.53

$11.04

$14.86

2 Week Range

Now: $10.35

$7.21

$16.88

Volume

482,316 shs

Average Volume

492,089 shs

Market Capitalization

$436.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88